Biopharmaceutical company Boehringer Ingelheim, which has U.S. operations in Ridgefield, has made a $50 million investment in a New York-based digital therapeutics company as part of a deal to transfer commercialization rights for an investigational schizophrenia treatment.
The investment is in Click Therapeutics, which co-developed CT-155 with Boehringer. Under the agreement, Click will take over responsibility for commercializing the therapy.
CT-155 is an app-based investigational treatment designed to help people with schizophrenia manage certain symptoms alongside standard medication. It has not been approved by regulators but received Breakthrough Device designation from the U.S. Food and Drug Administration in 2024.
In a Phase III clinical trial, the treatment showed a statistically significant reduction in certain negative symptoms of schizophrenia when used alongside standard antipsychotic treatment, according to the companies.
Boehringer will continue to lead completion of an ongoing study related to the treatment.
Financial terms beyond the investment were not disclosed.
